2-(tetrahydropyran-4-yl)propionic acid methyl ester | 502609-53-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2-(tetrahydropyran-4-yl)propionic acid methyl ester
• 英文别名: methyl 2-(oxan-4-yl)propanoate
• CAS: 502609-53-2
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: AWXDICOJNIUICW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(四氢-2H-吡喃-4-基)乙酸甲酯 、 碘甲烷 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 、 正庚烷 、 乙基苯 为溶剂， 反应 48.5h， 以85.1%的产率得到2-(tetrahydropyran-4-yl)propionic acid methyl ester
  参考文献：
  名称：

  REVERSE HYDROXAMIC ACID DERIVATIVES

  摘要：

  公开号：

  EP1431285B1

文献信息

• SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS
  申请人：Bignan Gilles

  公开号：US20110294780A1

  公开（公告）日：2011-12-01

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化以及与软骨形成有关的疾病），软骨发育不良，软骨肉瘤，慢性腰部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺疾病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，遗传性骨发育不全，骨溶解性骨转移，软骨软化症，骨质疏松症，帕金森病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的方法。
• [EN] PYRIDINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRIDINE COMME ANTAGONISTES DES RÉCEPTEURS 5-HT6
  申请人：SELVITA S A

  公开号：WO2014128223A1

  公开（公告）日：2014-08-28

  Compounds of formula (I), wherein X, Y, Z, R1-R7, m and n are as defined herein, exhibit 5-HT6 antagonistic activity and are thus useful for the treatment of certain CNS disorders. Methods of use of said compounds are also provided.

  式(I)的化合物，其中X、Y、Z、R1-R7、m和n如本文所定义，表现出5-HT6拮抗活性，因此对于治疗某些中枢神经系统疾病是有用的。同时还提供了使用这些化合物的方法。
• Reverse hydroxamic acid derivatives
  申请人：——

  公开号：US20040242928A1

  公开（公告）日：2004-12-02

  Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): 1 (wherein A is a hydrogen atom or the like; Ar 1 is an arylene or the like; Ar 2 is an optionally substituted aryl, a heteroaryl or the like; R 1 is a hydrogen atom, an alkyl or the like; R 2a is a substituted cycloaryl, a heterocycloaryl or the like) and a general formula (I): 2 (wherein A, Ar 1 , Ar 2 , and R 1 are the same as defined above and R 2 is an hydrogen atom, R 2a or the like) and salts thereof, which have TNF-&agr; converting enzyme (TACE) inhibitory activity.

  具有特定结构的反式羟胺酸衍生物，通式（Ia）表示如下：1（其中A是氢原子或类似物；Ar1是芳烃或类似物；Ar2是可选取代的芳基、杂环芳基或类似物；R1是氢原子、烷基或类似物；R2a是取代的环烷基、杂环环烷基或类似物），以及通式（I）2（其中A、Ar1、Ar2和R1的定义与上述相同，而R2是氢原子、R2a或类似物），以及其盐，具有TNF-α转化酶（TACE）抑制活性。
• ANTIVIRAL COMPOUNDS
  申请人：Cottell Jeromy J.

  公开号：US20140051626A1

  公开（公告）日：2014-02-20

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的过程和中间体。
• PYRIDINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS
  申请人：Selvita S.A.

  公开号：US20160009697A1

  公开（公告）日：2016-01-14

  Compounds of formula (I), wherein X, Y, Z, R 1 -R 7 , m and n are as defined herein, exhibit 5-HT 6 antagonistic activity and are thus useful for the treatment of certain CNS disorders. Methods of use of said compounds are also provided.

  式(I)的化合物，其中X、Y、Z、R1-R7、m和n的定义如本文所述，表现出5-HT6拮抗活性，因此对于治疗某些中枢神经系统疾病是有用的。同时也提供了所述化合物的使用方法。